Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
NCT ID: NCT04952272
Last Updated: 2024-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
50 participants
INTERVENTIONAL
2021-03-01
2036-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05420545
A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T
NCT05468190
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT06010875
RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT05122572
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
NCT07181720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
3. Assessing side effects and therapeutic efficacy after the combined treatments
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intratumor CpG-ODN Injection
CpG-ODN will be Injected into the tumor.
CpG-ODN
CAR-T cells secreting scFv against OX40
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CpG-ODN
CAR-T cells secreting scFv against OX40
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between18 and 80 years
* Life expectancy is greater than three months
Exclusion Criteria
* Life expectancy is less than three months
* Serious medical comorbidity
* Others
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhenfeng Zhang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital of Guangzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZZITCpG-013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.